|OliX Pharmaceuticals to Participate in BIO Partnering at JPM and Biotech Showcase 2022 Conferences|
|Date : 2022-03-22 View : 1109|
OliX Pharmaceuticals to Participate in BIO Partnering at JPM and Biotech Showcase 2022 Conferences
Suwon, Republic of Korea, January 03, 2022 – OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will hold one-on-one meetings at BIO Partnering at JPMfrom January 10-14, 2022. The Company’s management will also participate in Biotech Showcase 2022, being held virtually from January 10-12, 2022 and January 17-19, 2022.
Dong Ki Lee, Ph.D., Founder and Chief Executive Officer, Sun Woo Hong, Ph.D., Head of Research and Development, and June Park, Principal Scientist, will be available to discuss platform-based early discovery collaborations and licensing options for its RNAi therapeutic candidates, including OLX703A for hepatitis B, OLX702A for nonalcoholic steatohepatitis, OLX104C for androgenic alopecia, and other pipeline programs.
The events coincide with the annual J.P. Morgan Healthcare Conference, being held virtually, and offer various opportunities for licensing, collaboration, consulting and investment opportunities for life sciences companies.
|Prev||OliX Pharmaceuticals to Present at SMi 13th Annual RNA Therapeutics Conference|
|Next||OliX Pharmaceuticals Subsidiary mCureX Strengthens Scientific Advisory Board|